Percutaneous Transluminal Angioplasty Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Percutaneous Transluminal Angioplasty. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
PTA Registry - an Observational Study of Percutaneous Transluminal Angioplasty
Overview
Percutaneous transluminal angioplasty (PTA) is a minimally invasive procedure for dilating blood vessels in the treatment of peripheral artery disease. The aim of this registry is to collect prospectively and systematically clinical research data from patients undergoing PTA. This registry is an open-end observational study to assess the characteristics and outcomes in patients with undergoing PTA.
Primary outcome measures
- Patency rate [Time frame: 6 months]
- Creatinine level [Time frame: 2 Days after PTA]
Secondary outcome measures (5)
- Mortality [Time frame: 30 days]
- Days of Hospitalization [Time frame: 12 months]
- Ankle-Brachial Index [Time frame: 6 months and 12 months]
- walking distance [Time frame: 6 months and 12 months]
- Restenosis rate [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Patients undergoing PTA
Exclusion criteria
- < 18 years
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Germany · 1 center
- Division of Cardiology, Pulmonary Disease and Vascular Medicine — Düsseldorf
Publications
- Baasen S, Stern M, Wischmann P, Schremmer J, Sansone R, Spieker M, Wolff G, Bonner F, Quast C, Heiss C, Kelm M, Busch L. Endovascular Treatment of Flow-Limiting Iliofemoral Stenosis Improves Left Ventricular Diastolic Function in Patients With HFpEF by Reducing Aortic Pulsatile Load. Circ Heart Fail. 2024 Sep;17(9):e011258. doi: 10.1161/CIRCHEARTFAILURE.123.011258. Epub 2024 Sep 9. PMID 39247971
- Busch L, Heinen Y, Stern M, Wolff G, Ozaslan G, Tzetou K, Sansone R, Heiss C, Kelm M. Angioplasty of Flow-Limiting Stenosis Reduces Aortic and Brachial Blood Pressure in Patients With Peripheral Artery Disease. J Am Heart Assoc. 2021 Jul 20;10(14):e019724. doi: 10.1161/JAHA.120.019724. Epub 2021 Jul 6. PMID 34227407
Identifiers
NCT: NCT02728479 · PTA Registry